Zenas BioPharma reports Q2 2026 results, obexelimab BLA now accepted by FDA
FDA accepted the IgG4-RD application with a target decision date in May 2027, while the company posted a wider quarterly net loss and $673.9 million in cash.
SEC filing
Latest
1 story